| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 14
| Issue : 1 | Page : 1-7 |
|
|
Radiotherapy target volumes in esophageal cancer: The twisting kaleidoscope
Gautam Sarma, Jyotiman Nath, Biswajit Sarma
Department of Radiation Oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
Correspondence Address:
Dr. Biswajit Sarma
Department of Radiation Oncology, Dr. B Borooah Cancer Institute, Guwahati, Assam
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrcr.jrcr_25_22
|
|
|
Incidence of carcinoma esophagus accounts for approximately 6% of all gastrointestinal malignancies. According to GLOBOCAN 2020 data, 604,100 cases of carcinoma esophagus were detected (3.1% of total cases), and it was the 8th most common cancer in the world. The first choice of treatment for resectable esophageal cancer is surgery. Neoadjuvant radio-chemotherapy improved the overall survival (OS) of patients with advanced carcinomas of the esophagus by about 10% in 5 years, as shown by different studies. In unresectable cases, carcinoma esophagus definitive chemoradiation is the treatment of choice. Determination of the target volume of the esophagus has changed with time due to the advancement of technology. Determining the target volumes accurately is essential to achieve precise dose delivery to the targets. Controversies still exist between different regions and societies regarding target volume determination. However, the choice of the treatment volumes, techniques, and dose for optimal use must be individualized. Patients' disease status, preference, and comorbidities should also be considered while making decisions. This article will review the different target volumes, techniques, and doses used in various large trials used in definitive, neoadjuvant, and adjuvant studies.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
![JOURNAL_FULL_NAME]](images/logo.gif){kind=logo}
